A review of health records and other data revealed that persons who were overweight or obese lost more weight and pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's well-known competing weight loss medication.
The study, which was published on medRxiv ahead of peer review, found that 42.3% of patients taking tirzepatide, the active ingredient in Mounjaro and Zepbound, had lost at least 15% of their body weight within a year of starting treatment, compared with 19.3% of patients taking semaglutide, the main ingredient in Wegovy and Ozempic.
According to the findings, compared to patients on Ozempic, those taking Mounjaro had a 76% higher chance of losing at least 5% of their body weight, a more than twice as high chance of losing at least 10%, and a more than three times higher chance of losing at least 15% after adjusting for individual risk factors.
Researchers examined the weight loss trajectories of 9,193 patients getting Mounjaro and the same number of closely matched patients receiving Ozempic using electronic health records and pharmacy dispensing data in the absence of head-to-head randomised controlled trials comparing the two medications. About half of the participants had type 2 diabetes, with an average weight of 242 pounds (110 kg).
The study also discovered that after three months of treatment, patients on Mounjaro had lost 2.3% more body weight on average than those on Ozempic. The difference increased to 4.3% after six months, and the Mounjaro group dropped an additional 7.2% of their body weight on average after twelve months.
According to the researchers, there were comparable rates of gastrointestinal adverse events in each group.
Although Mounjaro and Ozempic are both prescribed for persons with type 2 diabetes, the researchers point out that half of the trial participants were only taking the medications to lose weight, which could have affected the findings.
In a statement sent by e-mail, Novo Nordisk "The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have (been) reported which evaluate Wegovy and tirzepatide."
A representative for Eli Lilly stated that even if one of their products is now authorised for weight reduction, the business does not support or encourage the use of any of its medications off-label.
A trial comparing the two injectable medications' weight-loss formulations is currently being place in individuals who are overweight or obese but do not have type 2 diabetes. We won't expect those findings until 2025.
A representative for Novo, meanwhile, noted that the study report included the following: "This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.”
(Source:www.cnbc.com)
The study, which was published on medRxiv ahead of peer review, found that 42.3% of patients taking tirzepatide, the active ingredient in Mounjaro and Zepbound, had lost at least 15% of their body weight within a year of starting treatment, compared with 19.3% of patients taking semaglutide, the main ingredient in Wegovy and Ozempic.
According to the findings, compared to patients on Ozempic, those taking Mounjaro had a 76% higher chance of losing at least 5% of their body weight, a more than twice as high chance of losing at least 10%, and a more than three times higher chance of losing at least 15% after adjusting for individual risk factors.
Researchers examined the weight loss trajectories of 9,193 patients getting Mounjaro and the same number of closely matched patients receiving Ozempic using electronic health records and pharmacy dispensing data in the absence of head-to-head randomised controlled trials comparing the two medications. About half of the participants had type 2 diabetes, with an average weight of 242 pounds (110 kg).
The study also discovered that after three months of treatment, patients on Mounjaro had lost 2.3% more body weight on average than those on Ozempic. The difference increased to 4.3% after six months, and the Mounjaro group dropped an additional 7.2% of their body weight on average after twelve months.
According to the researchers, there were comparable rates of gastrointestinal adverse events in each group.
Although Mounjaro and Ozempic are both prescribed for persons with type 2 diabetes, the researchers point out that half of the trial participants were only taking the medications to lose weight, which could have affected the findings.
In a statement sent by e-mail, Novo Nordisk "The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have (been) reported which evaluate Wegovy and tirzepatide."
A representative for Eli Lilly stated that even if one of their products is now authorised for weight reduction, the business does not support or encourage the use of any of its medications off-label.
A trial comparing the two injectable medications' weight-loss formulations is currently being place in individuals who are overweight or obese but do not have type 2 diabetes. We won't expect those findings until 2025.
A representative for Novo, meanwhile, noted that the study report included the following: "This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.”
(Source:www.cnbc.com)
